This trial is testing a new drug for people with rheumatoid arthritis to see if it is safe and has any adverse effects.
6 Primary · 9 Secondary · Reporting Duration: Up to 24 weeks
Experimental Treatment
Non-Treatment Group
47 Total Participants · 2 Treatment Groups
Primary Treatment: JNJ-67484703 · Has Placebo Group · Phase 1
Age 18 - 65 · All Participants · 6 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Alabama | 66.7% |
Indiana | 33.3% |
18 - 65 | 100.0% |
Pinnacle Research Group, LLC | 100.0% |
Did not meet criteria | 66.7% |
Met criteria | 33.3% |